循環腫瘍細胞市場：技術タイプ、製品タイプ、用途、がんタイプ、エンドユーザー別-2025-2030年世界予測

循環腫瘍細胞市場の2024年の市場規模は128億2,000万米ドルで、2025年にはCAGR 10.25%で141億米ドルに成長し、2030年には230億2,000万米ドルに達すると予測されています。

循環腫瘍細胞（CTC）の検査は、現代の腫瘍学において重要なフロンティアとして浮上しており、臨床診断と治療介入を再形成する洞察を提供しています。近年、CTCの理解が進み、がんを早期に発見し、病気の進行をリアルタイムでモニターし、治療戦略を微調整するためのツールが医療界に提供されています。この入門的概要は、CTCセグメントを支える市場力学、技術革新、戦略的開拓を詳細に調査するための舞台を整えるものです。

CTCは非侵襲的なバイオマーカーとして機能する可能性があるため、研究者やヘルスケア専門家はCTCの重要性にますます注目しており、それによってがん管理への個別化されたタイムリーなアプローチが可能になります。正確な診断方法に対する需要が高まる中、高度な分析技術と合理化された検出システムの相互作用が市場の急成長を促しています。広範な調査と進化する臨床要件により、CTCモニタリングは診断の進歩と治療の最適化の交差点に位置づけられるようになりました。

さらに、学術機関、診断センター、技術プロバイダー間の連携強化が技術革新のペースを加速し、CTCベースの検査の臨床的受容性を高めています。複雑性に満ちた状況の中で、この包括的な調査は、極めて重要な推進力と将来の機会を強調し、以降のセクションで続く議論の土台を築くものです。

循環腫瘍細胞市場の変革

循環腫瘍細胞法における最近の進歩とパラダイムシフトは、腫瘍学の診断と治療アプローチに革命をもたらしました。洗練された分子技術や新しい分離方法の出現は、臨床医のがん診断に対する捉え方を再定義しました。CTC解析のような技術革新は患者の治療計画を検証する上で中心的なものとなり、洗練された検出・分離技術は早期がんの同定とモニタリングにおいて新たな局面を切り開いた。

この急速な変革期は、最先端の研究と臨床応用の統合によって特徴づけられます。精密医療に集中的に焦点を当て、研究機関は進化する研究と治療のニーズに応えるため、一貫して検出機器を改良しています。免疫磁気分離とマイクロ流体ベースの分離の両方によって推進される最新のアプローチは、CTC評価の感度と特異性を高めています。こうした変革的なシフトは競合情勢をも再構築し、伝統的な診断法が革新的な技術介入とシームレスに組み合わされる新時代の到来を告げています。

このような大きな変化の中で、戦略的パートナーシップや分野横断的なコラボレーションが、市場の進歩をさらに促進しています。プロセスの再定義は現在、データ主導の洞察による迅速な臨床判断をサポートし、CTC分析の役割をがんとの闘いにおける重要な要素として高めています。この変革の旅は、技術、臨床需要、市場の進化の間のダイナミックな相互作用を反映しています。

循環腫瘍細胞市場の主なセグメンテーション洞察

循環腫瘍細胞市場をセグメント別に分析すると、技術の進歩や多様な応用分野に牽引される多面的な状況が明らかになります。技術的な観点から、市場は2つの主要カテゴリーに分類される：CTC分析とCTC検出・分離です。後者はさらに、免疫磁気分離やマイクロ流体ベースの分離などの高度な技術で構成され、より洗練された正確な方法への移行を反映しています。これらの微妙な技術的サブセグメントは、感度と信頼性の向上を推進する上で不可欠です。これと連動して、製品は機器、キット、試薬に大別され、効果的なCTC評価に必要なハードウェアと消耗品の両方が十分に対応できるようになっています。

アプリケーションレベルでは、市場は臨床診断と研究、医薬品開発の両方に対応しており、その影響力の大きさが際立っています。リアルタイムの疾患モニタリングだけでなく、包括的な調査や治療試験のために診断システムを調整する能力は、これらのソリューションの多用途性を強調しています。市場セグメンテーションでは、乳がん、大腸がん、肺がん、前立腺がんで市場を分類し、有病率が高く複雑な病態を持つがんに対応するCTC分析の臨床的妥当性をさらに強調しています。

最後に、エンドユーザーに基づくセグメンテーションは、診断センター、病院・診療所、研究・学術機関などでの多様な採用を強調しています。このようにセグメンテーションを重層的に行うことで、市場力学を深く理解することができ、利害関係者がさまざまな業種の異なるニーズに対応するために的を絞った戦略を立案するのに役立ちます。こうしたセグメンテーションの洞察を統合することで、現在の業績を評価し、将来の動向を予測するための明確な道筋が得られます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん支援ヘルスケアインフラの世界の拡大
    • がんの罹患率と世界の発症率の上昇により、循環腫瘍細胞技術の広範な調査と臨床導入が促進されています。
  • 抑制要因
    • 広範な臨床導入のための限定的な償還ポリシー
  • 機会
    • バイオテクノロジーの研究開発への投資の増加により、イノベーションと分析方法の改善が促進される
    • 次世代循環腫瘍細胞分析の継続的な進歩
  • 課題
    • 規制上のハードルと複雑な検証手順
• 市場セグメンテーション分析
  • 製品タイプ：循環腫瘍細胞機器の継続的な進歩により、ハイスループット分析が可能
  • エンドユーザー：診断センターによる循環腫瘍細胞プラットフォームの採用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 循環腫瘍細胞市場テクノロジーの種類別

• CTC分析
• CTCの検出と分離
  • 免疫磁気分離
  • マイクロ流体ベースの分離

第7章 循環腫瘍細胞市場：製品タイプ別

• 機器
• キットと試薬

第8章 循環腫瘍細胞市場：用途別

• 臨床診断と調査
• 医薬品開発

第9章 循環腫瘍細胞市場がんの種類別

• 乳がん
• 大腸がん
• 肺がん
• 前立腺がん

第10章 循環腫瘍細胞市場：エンドユーザー別

• 診断センター
• 病院とクリニック
• 調査・学術機関

第11章 南北アメリカの循環腫瘍細胞市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の循環腫瘍細胞市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの循環腫瘍細胞市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Advanced Cell Diagnostics, Inc.
• Bio-Techne Corporation
• BioFluidica
• Biolidics Limited
• Creatv MicroTech, Inc.
• Epic Sciences
• Fluxion Biosciences, Inc. by Cell Microsystems
• Greiner Bio-One International GmbH
• Ikonisys, Inc.
• LungLife AI, Inc.
• Menarini Silicon Biosystems
• Miltenyi Biotec GmbH
• Precision Medicine Group, LLC
• QIAGEN N.V.
• Rarecells Diagnostics
• ScreenCell
• SRI International
• STEMCELL Technologies, Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. CIRCULATING TUMOR CELL MARKET MULTI-CURRENCY
• FIGURE 2. CIRCULATING TUMOR CELL MARKET MULTI-LANGUAGE
• FIGURE 3. CIRCULATING TUMOR CELL MARKET RESEARCH PROCESS
• FIGURE 4. CIRCULATING TUMOR CELL MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. CIRCULATING TUMOR CELL MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. CIRCULATING TUMOR CELL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CIRCULATING TUMOR CELL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CIRCULATING TUMOR CELL MARKET DYNAMICS
• TABLE 7. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY IMMUNOMAGNETIC SEPARATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY MICROFLUIDIC-BASED SEPARATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CLINICAL DIAGNOSTICS & RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CIRCULATING TUMOR CELL MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 52. CANADA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES CIRCULATING TUMOR CELL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 79. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 81. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 84. CHINA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 85. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 87. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 90. INDIA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 91. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 97. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 103. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 109. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 115. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 121. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 127. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 133. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 139. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 145. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 152. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 158. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 164. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 170. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 176. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 182. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 188. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 190. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 193. ITALY CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 194. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 195. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 200. NIGERIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. NIGERIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 206. NORWAY CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 207. NORWAY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 212. POLAND CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. POLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 214. POLAND CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 215. POLAND CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 216. POLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 217. POLAND CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 218. QATAR CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 219. QATAR CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 220. QATAR CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 221. QATAR CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. QATAR CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 223. QATAR CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 224. RUSSIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. RUSSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 230. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 236. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 237. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 242. SPAIN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 243. SPAIN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 248. SWEDEN CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 249. SWEDEN CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 254. SWITZERLAND CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SWITZERLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 260. TURKEY CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 261. TURKEY CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 266. UNITED ARAB EMIRATES CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 267. UNITED ARAB EMIRATES CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 272. UNITED KINGDOM CIRCULATING TUMOR CELL MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 273. UNITED KINGDOM CIRCULATING TUMOR CELL MARKET SIZE, BY CTC DETECTION & ISOLATION, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM CIRCULATING TUMOR CELL MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM CIRCULATING TUMOR CELL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM CIRCULATING TUMOR CELL MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM CIRCULATING TUMOR CELL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 278. CIRCULATING TUMOR CELL MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 279. CIRCULATING TUMOR CELL MARKET, FPNV POSITIONING MATRIX, 2024

The Circulating Tumor Cell Market was valued at USD 12.82 billion in 2024 and is projected to grow to USD 14.10 billion in 2025, with a CAGR of 10.25%, reaching USD 23.02 billion by 2030.

The examination of circulating tumor cells (CTCs) has emerged as a critical frontier in modern oncology, offering insights that are reshaping clinical diagnostics and therapeutic interventions. In recent years, an evolution in the understanding of CTCs has provided the medical community with the tools to detect cancer earlier, monitor disease progression in real time, and fine-tune treatment strategies. This introductory overview sets the stage for a detailed exploration of the market dynamics, technological innovations, and strategic developments underpinning the CTC segment.

Researchers and healthcare professionals are increasingly focusing on the significance of CTCs due to their potential to serve as non-invasive biomarkers, thereby allowing a more personalized and timely approach to cancer management. With rising demand for precise diagnostic methods, the interplay between advanced analytical techniques and streamlined detection systems has catalyzed rapid market growth. Broad-based research and evolving clinical requirements have now positioned CTC monitoring at the intersection of diagnostic progress and therapeutic optimization.

Furthermore, intensified collaborations between academic institutions, diagnostic centers, and technology providers have accelerated the pace of innovation, thereby enriching the clinical acceptability of CTC-based tests. In a landscape teeming with complexities, this comprehensive exploration underscores the pivotal drivers and future opportunities, setting a foundation for the discussions that follow in subsequent sections.

Transformative Shifts in the Circulating Tumor Cell Landscape

Recent advancements and paradigm shifts in circulating tumor cell methodologies have revolutionized the diagnostic and therapeutic approach in oncology. The emergence of sophisticated molecular techniques and novel isolation methods has redefined how clinicians perceive cancer diagnostics. Innovations in technologies such as CTC analysis have become central in validating patient treatment plans, while refined detection and isolation techniques have spearheaded new dimensions in early cancer identification and monitoring.

This period of rapid transformation is characterized by the integration of cutting-edge research with clinical applications. With a concentrated focus on precision medicine, organizations are consistently refining detection instruments to cater to evolving research and treatment needs. Modern approaches driven by both immunomagnetic separation and microfluidic-based separation have enhanced the sensitivity and specificity of CTC assessments. These transformative shifts are also reshaping the competitive landscape, ushering in a new era where traditional diagnostic methods are seamlessly combined with innovative technological interventions.

Amidst these sweeping changes, strategic partnerships and cross-sector collaborations further catalyze market advancements. The redefinition of processes now supports faster clinical decisions with data-driven insights and has elevated the role of CTC analysis as a crucial component in the fight against cancer. This transformative journey reflects the dynamic interplay between technology, clinical demand, and market evolution.

Key Segmentation Insights in the Circulating Tumor Cell Market

The segmented analysis of the circulating tumor cell market reveals a multi-faceted landscape that is driven by technological advancements and diverse application areas. From a technological standpoint, the market is dissected into two main categories: CTC analysis and CTC detection and isolation. The latter further comprises advanced techniques such as immunomagnetic separation and microfluidic-based separation, reflecting a move towards more refined and accurate methods. These nuanced technological sub-segments are integral in driving enhancements in sensitivity and reliability. In tandem, the product landscape is broadly categorized into instruments, as well as kits and reagents, ensuring that both the hardware and consumables required for effective CTC assessment are well catered for.

At the application level, the market caters to both clinical diagnostics and research, along with drug development, thereby highlighting its expansive impact. The ability to tailor diagnostic systems not only for real-time disease monitoring but also for comprehensive research and therapeutic trials emphasizes the versatility of these solutions. The cancer type segmentation categorizes the market across breast, colorectal, lung, and prostate cancers, further underlining the clinical relevance of CTC analyses as it caters to cancers with high prevalence and complex pathogenesis.

Lastly, the segmentation based on end users underscores a diversified adoption across diagnostic centers, hospitals and clinics, and research and academic institutes. This layered approach to segmentation allows for an in-depth understanding of market dynamics, helping stakeholders design targeted strategies to address the distinct needs across different verticals. The synthesis of these segmentation insights provides a clear pathway to evaluate current performance and forecast future trends.

Based on Technology Type, market is studied across CTC Analysis and CTC Detection & Isolation. The CTC Detection & Isolation is further studied across Immunomagnetic Separation and Microfluidic-Based Separation.

Based on Product Type, market is studied across Instruments and Kits & Reagents.

Based on Application, market is studied across Clinical Diagnostics & Research and Drug Development.

Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.

Based on End Users, market is studied across Diagnostic Centers, Hospital & Clinics, and Research & Academic Institutes.

Key Regional Insights Shaping the Global Market

The global footprint of the circulating tumor cell market shows considerable variations across different regions. In the Americas, advanced healthcare infrastructure paired with an accelerated adoption of novel diagnostic methods has bolstered market growth, driven in part by increasing investments in clinical research and early detection initiatives. The region shows promise with well-connected networks facilitating rapid technology diffusion, which in turn contributes to enhanced patient outcomes.

Across Europe, the Middle East, and Africa, a concerted focus on refining healthcare services and smart investments in research infrastructure have laid the groundwork for market maturation. The region benefits from rigorous regulatory frameworks and collaborative efforts that foster innovation in CTC detection methods. Additionally, a progressive push towards the incorporation of new technologies has spurred market development in these areas.

In the Asia-Pacific region, robust economic growth combined with rising healthcare awareness and government initiatives has recently accelerated the market trajectory. This region is witnessing a significant transformation, driven by substantial investments in research, the establishment of specialized diagnostic centers, and the integration of leading-edge CTC analytical techniques in routine clinical practice. Such regional insights highlight distinctive growth drivers and provide pivotal data that shape the overall market outlook.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Growth

Market growth in the circulating tumor cell segment is further dictated by the contributions of several leading companies that have committed to advancing innovation and enhancing analytical capabilities. Industry players like Advanced Cell Diagnostics, Inc. and Bio-Techne Corporation have consistently pushed the boundaries of diagnostic technology, while BioFluidica and Biolidics Limited have carved out significant niches by refining detection efficiencies. Creatv MicroTech, Inc. stands out for developing integrative diagnostic instruments that complement evolving research needs.

Furthermore, contributions from Epic Sciences and Fluxion Biosciences, Inc. by Cell Microsystems have been pivotal in establishing robust methodologies for accurate cell isolation and analysis. Companies such as Greiner Bio-One International GmbH, Ikonisys, Inc., and LungLife AI, Inc. continue to innovate through the implementation of emerging technologies and strategic alliances. In addition, Menarini Silicon Biosystems and Miltenyi Biotec GmbH frequently deliver breakthroughs in both product reliability and assay precision. The strategic involvement of Precision Medicine Group, LLC, QIAGEN N.V., and Rarecells Diagnostics has further influenced market evolution by enriching the portfolio of available diagnostic tools.

The collective contributions of ScreenCell, SRI International, STEMCELL Technologies, Inc., Sysmex Corporation, and Thermo Fisher Scientific Inc. emphasize a collaborative industry approach vital to propelling new standards in CTC detection. This robust network of market participants reinforces the credibility of the sector and plays a critical role in shaping future trends and investment opportunities.

The report delves into recent significant developments in the Circulating Tumor Cell Market, highlighting leading vendors and their innovative profiles. These include Advanced Cell Diagnostics, Inc., Bio-Techne Corporation, BioFluidica, Biolidics Limited, Creatv MicroTech, Inc., Epic Sciences, Fluxion Biosciences, Inc. by Cell Microsystems, Greiner Bio-One International GmbH, Ikonisys, Inc., LungLife AI, Inc., Menarini Silicon Biosystems, Miltenyi Biotec GmbH, Precision Medicine Group, LLC, QIAGEN N.V., Rarecells Diagnostics, ScreenCell, SRI International, STEMCELL Technologies, Inc., Sysmex Corporation, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are positioned at a strategic crossroads, with opportunities to harness emerging trends and refine their competitive edge. It is critical to adopt a forward-thinking approach that emphasizes the integration of advanced detection technologies with robust clinical applications. Leaders should prioritize investments in research and consider collaborations that bridge the gap between academic breakthroughs and industrial innovation. In doing so, they can better tailor diagnostic solutions to meet the nuanced needs of varied cancer types and patient demographics.

Embracing digitalization, modern data analytics, and precision medicine is essential to optimize operational efficiencies and improve patient outcomes. Additionally, successful market players will benefit from aligning product development with evolving clinical trends, thereby ensuring that new tools are both scientifically robust and economically viable. By leveraging insights derived from global trends and regional market specifics, decision-makers can refine their strategic portfolios to capture emerging opportunities.

In a dynamically evolving marketplace, control over regulatory compliance, continuous innovation, and scalable solutions remains paramount. Industry leaders are encouraged to foster a culture that balances aggressive technological adoption with measured, evidence-based clinical strategies that serve to propel the sector forward.

Conclusion of the Executive Overview

As the circulating tumor cell market continues its rapid evolution, it is evident that the intersection of technological innovation and clinical utility remains a driving force behind its sustained growth. This executive summary encapsulates the complex interplay between enhanced technological methodologies, robust segmentation analyses, diverse regional growth patterns, and key industry players. By synthesizing the various dimensions of market dynamics, stakeholders gain a holistic understanding of the transformative shifts that are redefining cancer diagnostics and therapeutic approaches.

The forward momentum of the market is fueled by significant breakthroughs and strategic partnerships, reinforcing the need for an agile and forward-thinking approach. Ultimately, this comprehensive overview serves as both a reflective analysis of current market conditions and a strategic guide for navigating future opportunities.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Expansion of cancer supportive healthcare infrastructure worldwide
    • 5.1.1.2. Increasing prevalence of cancer and rising global incidence rates fueling extensive research and clinical adoption of circulating tumor cell technologies
  • 5.1.2. Restraints
    • 5.1.2.1. Limited reimbursement policies for widespread clinical adoption
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing investments in biotechnology research and development fostering innovation and improved analytical methods
    • 5.1.3.2. Ongoing advancements in next-generation circulating tumor cell analysis
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory hurdles and complex validation procedures
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Ongoing advancements in circulating tumor cell instruments to offer high-throughput analysis
  • 5.2.2. End Users: Growing adoption of circulating tumor cell platforms by diagnostic centers
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Circulating Tumor Cell Market, by Technology Type

• 6.1. Introduction
• 6.2. CTC Analysis
• 6.3. CTC Detection & Isolation
  • 6.3.1. Immunomagnetic Separation
  • 6.3.2. Microfluidic-Based Separation

7. Circulating Tumor Cell Market, by Product Type

• 7.1. Introduction
• 7.2. Instruments
• 7.3. Kits & Reagents

8. Circulating Tumor Cell Market, by Application

• 8.1. Introduction
• 8.2. Clinical Diagnostics & Research
• 8.3. Drug Development

9. Circulating Tumor Cell Market, by Cancer Type

• 9.1. Introduction
• 9.2. Breast Cancer
• 9.3. Colorectal Cancer
• 9.4. Lung Cancer
• 9.5. Prostate Cancer

10. Circulating Tumor Cell Market, by End Users

• 10.1. Introduction
• 10.2. Diagnostic Centers
• 10.3. Hospital & Clinics
• 10.4. Research & Academic Institutes

11. Americas Circulating Tumor Cell Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Circulating Tumor Cell Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Circulating Tumor Cell Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Strategic alliance between RGCC, PERABOI and PT Wapindo Jasaartha launches clinical study on liquid biopsy innovation for oncology in breast cancer patients
  • 14.3.2. Bio-Rad launches Celselect Slides 2.0 to enhance rare cell enrichment and improve liquid biopsy workflows
  • 14.3.3. Bio-Rad launches validated antibodies integrated with Celselect slide kits and the Genesis Cell Isolation System to enhance circulating tumor cell
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Advanced Cell Diagnostics, Inc.
• 2. Bio-Techne Corporation
• 3. BioFluidica
• 4. Biolidics Limited
• 5. Creatv MicroTech, Inc.
• 6. Epic Sciences
• 7. Fluxion Biosciences, Inc. by Cell Microsystems
• 8. Greiner Bio-One International GmbH
• 9. Ikonisys, Inc.
• 10. LungLife AI, Inc.
• 11. Menarini Silicon Biosystems
• 12. Miltenyi Biotec GmbH
• 13. Precision Medicine Group, LLC
• 14. QIAGEN N.V.
• 15. Rarecells Diagnostics
• 16. ScreenCell
• 17. SRI International
• 18. STEMCELL Technologies, Inc.
• 19. Sysmex Corporation
• 20. Thermo Fisher Scientific Inc.